Deferasirox (Exjade®) for the Treatment of Iron Overload

Publisher： Karger

E-ISSN： 1421-9662|122|2-3|165-173

ISSN： 0001-5792

Source： Acta Haematologica, Vol.122, Iss.2-3, 2009-11, pp. : 165-173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HJV Hemochromatosis, Iron Overload, and Hypogonadism in a Brazilian Man: Treatment with Phlebotomy and Deferasirox

By  

Acta Haematologica, Vol. 124, Iss. 4, 2010-11 ,pp. : 204-205

Karger

Access to resources Recommend Favorite

Loss of Transfusion Dependency Following Deferasirox Treatment of Iron Overload in a Woman with Myelofibrosis and Spherocytosis - a Case Report

By  

Oncology Research and Treatment, Vol. 36, Iss. 4, 2013-03 ,pp. : 205-208

Karger

Access to resources Recommend Favorite

Two-Year Analysis of Efficacy and Safety of Deferasirox Treatment for Transfusional Iron Overload in Sickle Cell Anemia Patients

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 113-118

Karger

Access to resources Recommend Favorite

CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload

By  

Oncology Research and Treatment, Vol. 39, Iss. 7-8, 2016-06 ,pp. : 424-431

Karger

Access to resources Recommend Favorite

Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox?

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 53, Iss. 9, 2013-09 ,pp. : 885-891

John Wiley & Sons Inc

Access to resources Recommend Favorite